Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:958276.
doi: 10.1155/2013/958276. Epub 2013 Jul 31.

Increasing the radioiodine dose does not improve cure rates in severe graves' hyperthyroidism: a clinical trial with historical control

Jose Miguel Dora  1 , Walter Escouto Machado, Vânia A Andrade, Rafael Selbach Scheffel, Ana Luiza Maia
Affiliations

Increasing the radioiodine dose does not improve cure rates in severe graves' hyperthyroidism: a clinical trial with historical control

Jose Miguel Dora et al. J Thyroid Res. 2013.

Abstract

Objective. It is generally accepted that higher doses of radioiodine ((131)I) improve cure rates in Graves' disease (GD). In this trial we sought to evaluate whether very high (131)I doses increase the efficacy of treatment in severe GD. Design. Clinical trial with historical control. Patients with GD and a goiter ≥48 mL were eligible for the study. The patients in the contemporaneous intervention cohort were treated with 250 μ Ci of (131)I/mL thyroid tissue, corrected by 24-RAIU values (Group 1; n = 15). A subgroup of patients with GD and a goiter ≥48 mL who were treated with 200 μ Ci of (131)I/mL/24-RAIU in a previously published randomized controlled trial served as a historical control group (Group 2; n = 15). The primary outcome evaluated was the one-year cure rate. Results. There were no significant baseline differences regarding age, gender, body mass index, smoking status, pretreatment with methimazole, thyroid volume, or thyroid hormone levels of the two treatment groups. The cumulative 12-month cure rate for the patients in Group 1 was 66.6%, a figure similar to the 12-month cure rate observed in Group 2 (60.0%; P = 0.99). Conclusions. Our results suggest that increasing the (131)I dose does not improve cure rates in severe GD. This trial is registered with ClinicalTrials.gov NCT01039818.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves indicating the responses of the two study groups to a single dose of 131I. The time to hyperthyroidism control was assessed by the Breslow test (P = 0.40).
See this image and copyright information in PMC

References

    1. Ross DS. Radioiodine therapy for hyperthyroidism. The New England Journal of Medicine. 2011;364(6):542–550. - PubMed
    1. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves’ disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid. 1999;9(12):1181–1188. - PubMed
    1. Jarlov AE, Hegedust L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clinical Endocrinology. 1995;43(3):325–329. - PubMed
    1. Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3488–3493. - PubMed
    1. Alexander EK, Larsen PR. High dose 131I therapy for the treatment of hyperthyroidism caused by Graves’ disease. Journal of Clinical Endocrinology and Metabolism. 2002;87(3):1073–1077. - PubMed

Associated data

LinkOut - more resources